Given Imaging Announces Participation at Upcoming Investor Conferences
November 08 2010 - 8:00AM
Marketwired
Given Imaging (NASDAQ: GIVN) today announced that Yuval Yanai,
Chief Financial Officer, will present at the following investor
conferences:
- The Lazard 7th Annual Healthcare Conference in New York City on
Wednesday, November 17, 2010 at 9:30 am ET.
- The Maxim Group Growth Conference in New York City on Thursday,
November 18, 2010 at 11:30 am ET.
To access live webcasts of these presentations, visit
www.givenimaging.com and click 'About Given Imaging.' The webcasts
will be available in the Investor Relations section. Replays will
be available for two weeks at the above-referenced website.
About Given Imaging Ltd.
Since 2001, Given Imaging has advanced gastrointestinal
visualization by developing innovative, patient-friendly tools
based on its PillCam® Platform. PillCam® capsule endoscopy uses
cutting-edge, wireless technology and advanced software to provide
physicians with natural images of the small intestine via PillCam®
SB, the esophagus through PillCam® ESO and the colon with PillCam®
COLON [PillCam® COLON is not cleared for use in the USA]. The
PillCam® capsules are miniature video cameras that patients ingest.
Given Imaging's other capsule products include Agile™ patency
capsule, to verify intestinal patency, and Bravo®, the only
wireless, catheter-free, 48-hour pH test commercially available for
pH testing to assess gastroesophageal reflux disease (GERD). In
April, 2010, Given Imaging acquired Sierra Scientific Instruments,
the leading provider of specialty GI diagnostic solutions and
pioneer of high-resolution manometry for assessing gastrointestinal
motility. Sierra Scientific is now a wholly-owned subsidiary of
Given Imaging. Given Imaging's headquarters, manufacturing and
R&D facilities are located in Yoqneam, Israel, with operating
subsidiaries in the United States, Germany, France, Japan,
Australia and Hong Kong. For more information, please visit
www.givenimaging.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, projections about our
business and our future revenues, expenses and profitability.
Forward-looking statements may be, but are not necessarily,
identified by the use of forward-looking terminology such as "may,"
"anticipates," "estimates," "expects," "intends," "plans,"
"believes," and words and terms of similar substance.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual events,
results, performance, circumstances or achievements of the Company
to be materially different from any future events, results,
performance, circumstances or achievements expressed or implied by
such forward-looking statements. Factors that could cause actual
events, results, performance, circumstances or achievements to
differ from such forward-looking statements include, but are not
limited to, the following: (1) our ability to develop and bring to
market new products, (2) our ability to successfully complete any
necessary or required clinical studies with our products, (3) our
ability to receive regulatory clearance or approval to market our
products or changes in regulatory environment, (4) our success in
implementing our sales, marketing and manufacturing plans, (5) the
level of adoption of our products by medical practitioners, (6) the
emergence of other products that may make our products obsolete,
(7) lack of an appropriate bowel preparation materials to be used
with our PillCam COLON capsule, (8) protection and validity of
patents and other intellectual property rights, (9) the impact of
currency exchange rates, (10) the effect of competition by other
companies, (11) the outcome of significant litigation, (12) our
ability to obtain reimbursement for our product from government and
commercial payors, (13) quarterly variations in operating results,
(14) the possibility of armed conflict or civil or military unrest
in Israel, (15) the impact of global economic conditions, (16) our
ability to successfully integrate acquired businesses, (17) changes
and reforms in applicable healthcare laws and regulations and (18)
other risks and factors disclosed in our filings with the U.S.
Securities and Exchange Commission, including, but not limited to,
risks and factors identified under such headings as "Risk Factors,"
"Cautionary Language Regarding Forward-Looking Statements" and
"Operating Results and Financial Review and Prospects" in the
Company's Annual Report on Form 20-F for the year ended December
31, 2009. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Except for the Company's ongoing obligations to
disclose material information under the applicable securities laws,
it undertakes no obligation to release publicly any revisions to
any forward-looking statements, to report events or to report the
occurrence of unanticipated events.
For further information contact: Fern Lazar/David Carey Lazar
Partners Ltd. 1-212-867-1768 Email Contact/ Email Contact
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024